Sublingual morphine: Efficacy reviewed

Journal of Pain and Symptom Management

Volumn 16, Issue 3, 1998, Pages 184-192

  Coluzzi, Paul H ^a,b  

^a ST JOSEPH HOSPITAL   (United States)

^b Oncology Center   (United States)

Author keywords

Cancer pain; Opioids; OTFC; Pharmacokinetics; Sublingual morphine

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; NALOXONE; OXYCODONE;

ANALGESIA; CANCER PAIN; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RECTAL DRUG ADMINISTRATION; REVIEW; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; HUMANS; MORPHINE;

EID: 0032167534     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(98)00046-3     Document Type: Review

References (30)

1. 1. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-1132.
2. 2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990;41:273-281.
3. 3. Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992;50:151-155.
4. 4. Khojasteh A, Evans W, Reynolds RD, Thomas G, Savarese JJ. Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol 1987;5:956-961.
5. 5. Deschamps M, Band PR, Hislop TG, Rusthoven J, Iscoe N, Warr D. The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. J Pain Symptom Manage 1992;7:384-392.
6. 6. Robison JM, Wilkie DJ, Campbell B. Sublingual and oral morphine administration. Nurs Clin North Am 1995;30:725-743.
7. 7. Foley KM. Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs 1995;6(suppl 3):4-13.
8. 8. Ripamonti C, Bruera E. Rectal, buccal, and sublingual narcotics for the management of cancer pain. J Palliat Care 1991;7:30-35.
9. 9. De Boer AG, De Leede LGJ, Breimer DD. Drug absorption by sublingual and rectal routes. Br J Anaesth 1984;56:69-82.
10. 10. Slattery PJ, Boas RA. Newer methods of delivery of opiates for relief of pain. Drugs 1985;30:539-551.
11. 11. Pitorak EF, Kraus JC. Pain control with sublingual morphine. The advantages for hospice care. Am J Hospice Care 1987;March/April:39-41.
12. 12. Pitorak EF. Pain control with sublingual or buccal morphine. Oncol Nurs Forum 1991;18:941.
13. 13. Karl HW, Rosenberger JL, Larach MG, Ruffle JM. Transmucosal administration of midazolam for premedication of pediatric patients. Comparison of the nasal and sublingual routes. Anesthesiology 1993;78:885-891.
14. 14. Bullingham RES, McQuay HJ, Dwyer D, Allen MC, Moore RA. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981;12:117-122.
15. 15. Edge WG, Cooper GM, Morgan M. Analgesic effects of sublingual buprenorphine. Anaesthesia 1979; 34:463-467.
16. 16. De Conno F, Ripamonti C, Sbanotto A, Barletta L. A clinical note on sublingual buprenorphine. J Palliat Care 1993;9:44-46.
17. 17. Pannuti F, Rossi AP, Iafelice G, et al. Control of chronic pain in very advanced cancer patients with morphine hydrochloride administered by oral, rectal, and sublingual routes: clinical report and preliminary results on morphine pharmacokinetics. Pharmalogical Res Comm 1982;14:369-380.
18. 18. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-337.
19. 19. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990;47:12-19.
20. 20. Davis T, Miser AW, Loprinzi CL, et al. Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. The Hospice Journal 1993;9: 85-90.
21. 21. McQuay HJ, Moore RA, Bullingham RES. Sublingual morphine, heroin, methadone, and buprenorphine: kinetics and effects. In: Foley KM, Inturrisi CE, eds. Advances in pain research and therapy, vol 8. New York: Raven, 1986:407-412.
22. 22. Bell MDD, Mishra P, Weldon BD, Murray GR, Calvey, TN, Williams NE. Buccal morphine - a new route for analgesia? Lancet 1985;1:71-73.
23. 23. Fisher AP, Vine P, Whitlock J, Hanna M. Buccal morphine premedication. A double-blind comparison with intramuscular morphine. Anaesthesia 1986; 41:1104-1111.
24. 24. Lamer TJ. Treatment of cancer pain: when orally administered medications fail. Mayo Clin Proc 1994;69:473-480.
25. 25. Coluzzi PH. Oral patient-controlled analgesia. Semin Oncol 1997;24:S35-S42.
26. 26. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991;75:223-229.
27. 27. Coluzzi P. A titration study of oral transmucosal fentanyl citrate for breakthrough pain in cancer patients [Abstract]. Proc Am Soc Clin Oncol 1997;16: 41a.
28. 28. Fine PG, Marcus M, De Boer AJ, Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991;45:149-153.
29. 29. Sevarino FB, Ginsber B, Lichtor JL, Joshi GP, Nordbrock E, Busch MA. Oral transmucosal fentanyl citrate (OTFC) compared with IV morphine for acute pain in patients following abdominal surgery. Anesth Analg 1997;84:S330.
30. 30. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Clinical practice guideline no. 9. AHCPR publication no. 94-0592. Rockville, MD: Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, 1994.